These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 8475950)
41. Mobilization of lead by calcium disodium edetate. A reappraisal. Chisolm JJ Am J Dis Child; 1987 Dec; 141(12):1256-7. PubMed ID: 3120574 [No Abstract] [Full Text] [Related]
42. Disappearance of immune deposits with EDTA chelation therapy in a case of IgA nephropathy. Lin JL; Lim PS Am J Nephrol; 1992; 12(6):457-60. PubMed ID: 1292346 [TBL] [Abstract][Full Text] [Related]
43. [Hyperuricemia due to renal failure, autosomal dominant polycystic kidney disease and lead nephropathy]. Hosoya T Nihon Rinsho; 2003 Jan; 61 Suppl 1():294-8. PubMed ID: 12629734 [No Abstract] [Full Text] [Related]
44. [Gout and hyperuricemia associated with lead poisoning]. Lejeune E; Tolot F; Meunier P Rev Rhum Mal Osteoartic; 1969 Apr; 36(4):161-73. PubMed ID: 5402943 [No Abstract] [Full Text] [Related]
45. Chelated lead and bone lead. Tell I; Somervaille LJ; Nilsson U; Bensryd I; Schütz A; Chettle DR; Scott MC; Skerfving S Scand J Work Environ Health; 1992 Apr; 18(2):113-9. PubMed ID: 1604271 [TBL] [Abstract][Full Text] [Related]
46. Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease: Possible Role for Chelation Therapy. Glicklich D; Shin CT; Frishman WH Cardiol Rev; 2020; 28(6):312-318. PubMed ID: 32040019 [TBL] [Abstract][Full Text] [Related]
47. The clinical differentiation of lead gout from primary gout. Emmerson BT Arthritis Rheum; 1968 Oct; 11(5):623-34. PubMed ID: 5680985 [No Abstract] [Full Text] [Related]
48. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Lin JL; Lin-Tan DT; Yu CC; Li YJ; Huang YY; Li KL Kidney Int; 2006 Jun; 69(11):2049-56. PubMed ID: 16641918 [TBL] [Abstract][Full Text] [Related]
53. Triglyceride concentrations in primary gout and gout of chronic lead nephropathy. Emmerson BT; Knowles BR Metabolism; 1971 Aug; 20(8):721-9. PubMed ID: 5568414 [No Abstract] [Full Text] [Related]
54. Elevated lead burden in Chinese patients without occupational lead exposure. Lin JL; Lim PS Miner Electrolyte Metab; 1992; 18(1):1-5. PubMed ID: 1406500 [TBL] [Abstract][Full Text] [Related]
55. Lead nephrotoxicity and associated disorders: biochemical mechanisms. Nolan CV; Shaikh ZA Toxicology; 1992; 73(2):127-46. PubMed ID: 1319092 [TBL] [Abstract][Full Text] [Related]
56. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Lin JL; Ho HH; Yu CC Ann Intern Med; 1999 Jan; 130(1):7-13. PubMed ID: 9890856 [TBL] [Abstract][Full Text] [Related]
57. Purine metabolism in patients with gout: the role of lead. Miranda-Carús E; Mateos FA; Sanz AG; Herrero E; Ramos T; Puig JG Nephron; 1997; 75(3):327-35. PubMed ID: 9069456 [TBL] [Abstract][Full Text] [Related]
59. Low-level environmental exposure to lead and progressive chronic kidney diseases. Lin JL; Lin-Tan DT; Li YJ; Chen KH; Huang YL Am J Med; 2006 Aug; 119(8):707.e1-9. PubMed ID: 16887418 [TBL] [Abstract][Full Text] [Related]
60. The role of lead in gout nephropathy reviewed: pathogenic or associated factor? Miranda ME; Puig JG; Mateos FA; Ramos TH; Herrero E; González A; Gil A; Vázquez JO Adv Exp Med Biol; 1991; 309A():209-12. PubMed ID: 1789210 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]